Trial Profile
Multiple-Dose, Dose-Escalation Study to Assess the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of LY3303560 in Patients With Mild Cognitive Impairment Due to Alzheimer's Disease or Mild to Moderate Alzheimer's Disease
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 12 Oct 2023
Price :
$35
*
At a glance
- Drugs Zagotenemab (Primary) ; Florbetapir F 18; Flortaucipir-F-18
- Indications Alzheimer's disease; Mild cognitive impairment
- Focus Adverse reactions
- Sponsors Eli Lilly and Company (India) Pvt. Ltd; Eli Lilly Japan
- 06 Oct 2023 Number of treatment arms have been increased from 2 to 3 by the addition of Experimental: 210 mg LY3303560 arm.
- 02 Jul 2019 Status changed from active, no longer recruiting to completed.
- 23 Aug 2018 Planned End Date changed from 1 Jun 2020 to 5 Jun 2020.